Socioeconomic burden of cystic fibrosis in Canada.
Humans
Cystic Fibrosis
/ economics
Canada
/ epidemiology
Cost of Illness
Female
Male
Adult
Health Care Costs
/ statistics & numerical data
Adolescent
Young Adult
Child
Health Expenditures
/ statistics & numerical data
Child, Preschool
Caregivers
/ economics
Socioeconomic Factors
Infant
Absenteeism
Prevalence
Middle Aged
Registries
cystic fibrosis
health economist
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
11
01
2024
accepted:
11
07
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
Cost of illness studies are important tools to summarise the burden of disease for individuals, the healthcare system and society. The lack of standardised methods for reporting costs for cystic fibrosis (CF) makes it difficult to quantify the total socioeconomic burden. In this study, we aimed to comprehensively report the socioeconomic burden of CF in Canada. The total cost of CF in Canada was calculated by triangulating information from three sources (Canadian CF Registry, customised Burden of Disease survey and publicly available information). A prevalence-based, bottom-up, human capital approach was applied, and costs were categorised into four perspectives (ie, healthcare system, individual/caregiver, variable (ie, medicines) and society) and three domains (ie, direct, indirect and intangible). All costs were converted into 2021 Canadian dollars (CAD) and adjusted for inflation. The cost of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies was excluded. The total socioeconomic burden of CF in Canada in 2021 across the four perspectives was $C414 million. Direct costs accounted for two-thirds of the total costs, with medications comprising half of all direct costs. Out-of-pocket costs to individuals and caregivers represented 18.7% of all direct costs. Indirect costs representing absenteeism accounted for one-third of the total cost. This comprehensive cost of illness study for CF represents a community-oriented approach describing the socioeconomic burden of living with CF and serves as a benchmark for future studies.
Sections du résumé
BACKGROUND
BACKGROUND
Cost of illness studies are important tools to summarise the burden of disease for individuals, the healthcare system and society. The lack of standardised methods for reporting costs for cystic fibrosis (CF) makes it difficult to quantify the total socioeconomic burden. In this study, we aimed to comprehensively report the socioeconomic burden of CF in Canada.
METHODS
METHODS
The total cost of CF in Canada was calculated by triangulating information from three sources (Canadian CF Registry, customised Burden of Disease survey and publicly available information). A prevalence-based, bottom-up, human capital approach was applied, and costs were categorised into four perspectives (ie, healthcare system, individual/caregiver, variable (ie, medicines) and society) and three domains (ie, direct, indirect and intangible). All costs were converted into 2021 Canadian dollars (CAD) and adjusted for inflation. The cost of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies was excluded.
RESULTS
RESULTS
The total socioeconomic burden of CF in Canada in 2021 across the four perspectives was $C414 million. Direct costs accounted for two-thirds of the total costs, with medications comprising half of all direct costs. Out-of-pocket costs to individuals and caregivers represented 18.7% of all direct costs. Indirect costs representing absenteeism accounted for one-third of the total cost.
CONCLUSION
CONCLUSIONS
This comprehensive cost of illness study for CF represents a community-oriented approach describing the socioeconomic burden of living with CF and serves as a benchmark for future studies.
Identifiants
pubmed: 39122474
pii: 11/1/e002309
doi: 10.1136/bmjresp-2024-002309
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: AS, BSQ, SS and WDW received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Vertex Pharmaceuticals, Educational events (BSQ and AS), Vyaire Medical (SS), Canadian Agency for Drugs and Technologies in Health (WDW) and Formulary Management Expert Committee (WDW). SS received consulting fees from Chiesi Farmaceutricals and Ndd technologies. PDWE, KS, ZMC, EM, JW and SYC are employees of Cystic Fibrosis Canada.